Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BIRC3 (encoding cIAP2) variants are associated with Crohn’s Disease.

ABSTRACT: The baculoviral IAP repeat-containing 3 (BIRC3) gene encodes the Cellular Inhibitor of Apoptosis Protein 2 (cIAP2) a regulator of innate immune pathways including TNFα receptor signaling. We identified 5 heterozygous and 3 homozygous rare damaging BIRC3 variants in 13 patients from 9 independent families who presented with Crohn’s Disease (CD) between 2 months and 31 years of age. A knock-in mouse model of the BIRC3 variant (cIAP2H312Y/+) identified in two independent CD families had increased susceptibility to DSS-induced colitis and ciap−/+ zebrafish developed spontaneous colitis. Transcriptome analysis showed that reduced BIRC3 expression led to the induction of several TNFa responsive genes including NFKB2. Functional studies showed that all cIAP2 variants had impaired inhibition of NFκB2 activity and increased cell death when induced by TNFa. Finally, cIAP2H312Y/+ mice treated with apoptosis or RIPK1 inhibitors had improved clinical outcomes. Our study demonstrates that BIRC3 variants results in dysregulation of NFκB2 signaling leading to in CD.

ORGANISM(S): Mus musculus Danio rerio

PROVIDER: GSE299375 | GEO | 2026/07/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy

Project description:Glioblastomas (GBM) are routinely treated with high doses of ionizing radiation (IR), yet these tumors recur quickly, and the recurrent tumors are highly therapy resistant. Here, we report that IR-induced senescence of tumor cells counterintuitively spurs GBM recurrence, driven by the senescence-associated secretory phenotype (SASP). We find that irradiated GBM cell lines and patient derived xenograft (PDX) cultures senesce rapidly in a p21-dependent manner. Senescent glioma cells upregulate SASP genes and secrete a panoply of SASP factors, prominently interleukin IL-6, an activator of the JAK-STAT3 pathway. These SASP factors collectively activate the JAK-STAT3 and NF-kB pathways in non-senescent GBM cells, thereby promoting tumor cell proliferation and SASP spreading. Transcriptomic analyses of irradiated GBM cells and the TCGA database reveal that the cellular inhibitor of apoptosis protein 2 (cIAP2), encoded by the BIRC3 gene, is a critical survival factor for senescent glioma cells. Senescent GBM cells not only upregulate BIRC3 but also induce BIRC3 expression and promote radioresistance in non-senescent tumor cells. We find that SMAC mimetics targeting cIAP2 act as novel senolytics that trigger apoptosis of senescent GBM cells with minimal toxicity towards normal brain cells. Finally, using both PDX and syngeneic mouse models of GBM, we show that the SMAC mimetic birinapant, administered as an adjuvant therapy after radiotherapy, can eliminate senescent GBM cells and prevent the emergence of recurrent tumors. Taken together, our results clearly indicate that significant improvement in GBM patient survival may become possible in the clinic by eliminating senescent cells arising after radiotherapy

2025-01-17 | GSE271928 | GEO

Nfkb2 deficiency and its impact on the murine small intestinal mucosa

Project description:The alternative (non-canonical) nuclear factor-kappa B (NF-κB) signalling pathway predominantly regulates the function of the p52/RelB heterodimer. Germline Nfkb2 deficiency in mice leads to loss of p100/p52 protein and offers protection against a variety of gastrointestinal conditions, such as azoxymethane/dextran sulfate sodium (DSS)-induced colitis-associated cancer and lipopolysaccharide (LPS)-induced small intestinal epithelial apoptosis. However, the common underlying protective mechanisms are not yet fully understood. Here we applied RNA sequencing and identified a B-lymphocyte defect as the major signature in the small intestinal mucosa of naïve adult Nfkb2-/- mice. Proteomics analysis also revealed a dramatic decrease in small intestinal immunoglobulin A levels, and this was validated by quantitative ELISA in both small intestinal lysates and serum. Moreover, the numbers of IgA-producing, CD138+ve plasma cells were also reduced in the lamina propria of the small intestinal villi of Nfkb2-/- mice. This phenotype was even more striking in the small intestinal mucosa of RelB-/- mice, although these mice were equally sensitive to LPS-induced intestinal apoptosis as their RelB+/+ wild-type counterparts. Therefore, p52 deficiency offers resistance to LPS-induced intestinal apoptosis and appears to regulate the plasma cell population within the gut.

2022-07-31 | E-MTAB-11018 | biostudies-arrayexpress

Expression data from mouse colon tissue in activated T cell transfer colitis model treated with MEK inhibitor or anti-TNFa antibody

Project description:We analyzed publicly available mucosal gene expression data from Crohn's disease (CD) patients pre- and post-infliximab therapy and found that a series of gene expression signature that remains abnormal even if patients achieve clinical remission. Using CMap approach to discover novel therapeutic target for untreatable mechanism of anti-TNFa mAb therapy, we have identified MEK inhibitor exhibiting negatively-correlated effects on reference signature match infliximab therapy untreatable signature. Our findings provide the rationale for testing MEK inhibitor to identify a novel mechanism of action for CD. Using an activated T cell trasnfer colitis model, a highly selective MEK inhibitor showed therapeutic efficacy and improved the histological changes. To dissect molecular mechanisms, we performed global gene expression profile by RNA-sequencing on the Ion Torrent platform to identify broad scale changes in gene expression treated with MEK inhibitor compared to anti-TNFa mAb.

2018-02-25 | GSE108052 | GEO

Core Ileal Transcriptome in Pediatric Crohn Disease

Project description:We report the global pattern of ileal gene expression in a cohort of 359 treatment-naïve pediatric Crohn Disease, Ulcerative Colitis patients and controls. We focus on genes with consistent altered expression in inflamed and unaffected ileum of CD [ileal-involved CD (iCD) and non-invloved ileal CD (cCD)], but not in the ileum of ulcerative colitis or control.

2014-07-24 | GSE57945 | GEO

Altered Intestinal Microbiota-Host Mitochondria Crosstalk in New Onset Crohn’s Disease

Project description:Intestinal microbial dysbiosis is associated with Crohn’s disease (CD). However, the mechanisms leading to the chronic mucosal inflammation that characterizes this disease remain unclear. To evaluate causality and mechanisms of disease, we conducted a systems level study of the interactions between the gut microbiota and host in new-onset pediatric patients. We report an altered host proteome in CD patients indicative of impaired mitochondrial functions. A downregulation of mitochondrial proteins implicated in H2S detoxification was observed, while the relative abundance of H2S microbial producers was increased. Network correlation analysis identified Atopobium parvulum as the central hub of H2S producers. Gnotobiotic and conventionalized colitis-susceptible interleukin-10-deficient (Il10-/-) mice demonstrated that A. parvulum induced colitis, a phenotype requiring the presence of the intestinal microbiota. Administration of bismuth, a H2S scavenger, prevented A. parvulum-induced colitis in Il10-/- mice. This study identified host-microbiota interactions that are disturbed in CD patients providing mechanistic insights on CD pathogenesis.

2016-09-29 | PXD002882 | Pride

Genentech IBD Fecal Proteomics

Project description:Comparison of the human fecal proteomes from healthy control (HC), ulcerative colitis (UC), and Crohn's disease (CD) stool. Two cohorts: Cohort 1 with N=5 samples from each group (HC, UC, CD) and Cohort 2 with N=20 samples from HC, and N=10 samples each from UC and CD.

2022-04-11 | MSV000089237 | MassIVE

Deregulated megakaryocytic maturation, mitochondrial function and inflammatory signalling in CYCS(c.292T>C)-related thrombocytopenia

Project description:The human CYCS gene encodes for Cytochrome C, a mitochondrial protein with important cellular functions, including apoptosis and energy production. CYCS variants have been linked to CYCS-related thrombocytopenia, a mild autosomal dominant type of inherited thrombocytopenia. Here we report a novel heterozygous variant of the CYCS gene, c.292T>C, p.(Tyr98His) in a Greek family with thrombocytopenia. The functional role of the novel variant has been examined in several cellular processes to delineate the mechanisms underlying the thrombocytopenic phenotype of the patients. In megakaryocytes, the novel variant has been associated with irregular apoptosis, ATP production, superoxidase activity and maturation. Transcriptomic data have validated the deregulation of these cellular processes and have provided information about the effect of the variant on Tumor Necrosis Factor A (TNFA) signaling. TNFA via Nuclear Factor Kappa B (NFKB) pathway has been positively enriched in megakaryocytes carrying the variant, possibly triggering the observed deregulation of apoptosis and differentiation. This study has provided insights on the novel CYCS variant revealing a connection to the thrombocytopenic phenotype through deregulated apoptosis, energy production, differentiation and TNFA via NFKB signaling in megakaryocytes, providing future opportunities to therapeutically target the deregulated pathways in CYCS-related thrombocytopenias.

2026-01-08 | GSE290319 | GEO

ITGAV variants are associated with immune dysregulation, brain abnormalities, and very early onset Inflammatory Bowel Disease

Project description:Integrin alpha–V (ITGAV) forms heterodimers with beta subunits to regulate several cellular processes including transforming growth factor β (TGF-β) signaling. We examined three unrelated families with common disease features including two children born with congenital brain anomalies and later development of immune dysregulation, atopy, and colitis, and three fetuses with brain and developmental defects. Using whole exome and RNA sequencing and functional studies, we demonstrate that biallelic ITGAV variants caused abnormal splicing or mislocalized protein that led to dysregulated TGF-β signaling in these families. Furthermore, knockout itgav (-/-) zebrafish embryos developed brain defects with loss of microglia and juvenile itgav (-/-) zebrafish developed colitis. Together, we show the critical role of ITGAV in immune regulation and gut and brain homeostasis and disease pathogenesis.

2024-09-30 | GSE248975 | GEO

Genome-wide gene expression differences between Crohn’s and ulcerative colitis from endoscopic pinch biopsies:

Project description:Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBD) with variable, overlapping clinical features and complex pathophysiologies. To identify pathogenic processes underlying these disease subtypes, using single endoscopic pinch biopsies to estabolish 36 expression profiles, we elucidated gene expression patterns of active and inactive areas of UC and CD, and compared these to infectious colitis and healthy controls. Keywords: RNA

2007-03-01 | GSE6731 | GEO

AhmedMobeen2021 - NF-kB Activation Model

Project description:NF-kappaB Activation Model includes the activation of both NFKB1:RELA and NFKB2:RELB for Canonical and Non-Canonical Pathway respectively. The model includes the pathway model integrated with post-translational modifications of NF-kB subunits that regulate the NFKB1:RELA and NFKB2:RELB activity. The processes that are regulated by NF-kB pathway can be monitored through following readouts NFKB1:RELA Activity, NFKB2:RELB Activity, Degraded RelA, Degraded RelB, Degraded IkB, Degraded NIK, Apoptosis, Tumour, Antiviral Activity, B Cell Growth and Cell Migration. However, last 5 processes above are also influenced by other pathways too, therefore while making predictions, caution has to be exercised.

2022-05-27 | MODEL2001290001 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data